Clondalkin Group Invests For Labels Market
Published: August 22nd, 2013
Clondalkin Group has invested over €1,000,000 in new technologies to further enhance its Specialist Packaging Pharma & Healthcare business.
The investment includes the installation of a Gallus ECS 340 press at Clondalkin Pharma & Healthcare Kimbolton to expand high quality, efficient label production capabilities offered to customers. The 9 colour UV press features 340mm wide print, cold foil and reverse print capabilities, the company said in a press release.
In addition, significant upgrades to two existing presses have been completed at Clondalkin Pharma & Healthcare Hull to strengthen the business' capabilities in multi ply labels. A Gallus EM 260 flexo press has been upgraded with a new re-register unit plus two additional print heads to enable label production in 9 colours and up to 4 layers. Upgrades to an MPS flexo press include an additional print head taking it up to 10 colours and a new web shifting unit allowing production of a 5 ply label in a single pass.
"The investment creates two distinctive but complementary site offerings. Hull has a strong reputation for quality and innovation in the multi ply label sector which is highly valued by European brand owners and these significant upgrades strengthen this proposition. Kimbolton is now fully equipped to service the single ply pharma, cosmetics and toiletries market,” said Malcolm Farnan, European sales director, Clondalkin Group Specialist Packaging Division.
“ We are very excited by these investments which significantly enhance our product and service capabilities and we are very pleased with customer interest in these service innovations," Farnan added.
Clondalkin Group is an international producer of value-added packaging products and services with over 35 production locations in 8 different countries throughout Europe and North America and annual sales in excess of €700 million a year, employing around 4,000 people.